Cellectis Sub-Licenses Genomic Engineering IP to GlaxoSmithKline | GenomeWeb
NEW YORK (GenomeWeb News) — Cellectis has sub-licensed to GlaxoSmithKline patents for a process used to replace, remove, or insert genes in a genome by homologous recombination, Cellectis said Friday.
 
The company, which licensed the technology from the Pasteur Institute, said GlaxoSmithKline will use it in its drug research for in vitro and in vivo “modifications and manipulations of genetic material.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.